Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rolls-Royce CEO's pay drops by almost £10m

(Sharecast News) - Rolls-Royce chief executive officer Tufan Erginbilgic saw his pay package drop by nearly £10m in 2024, it emerged on Thursday, despite leading the company through a dramatic financial turnaround. His total remuneration fell to £4.1m from £13.6m in the prior year, largely due to the expiration of a one-time £7.5m share award he received upon joining Rolls-Royce to compensate for lost earnings from his previous role.

The reduction also reflected a decrease in Erginbilgic's annual incentive plan payout, which dropped from £4.6m to £2.5m under an older compensation structure.

Rolls-Royce had since revised its executive remuneration scheme, introducing separate bonus and long-term incentive plans for future years.

While his total pay fell, Erginbilgic's base salary rose from £875,000 to £1.1m and was set for a further 5% increase in 2025.

His pay adjustments came amid a period of significant recovery for Rolls-Royce, which recently reinstated dividends, launched a £1bn share buyback and upgraded its profit forecast for 2024.

Since taking over in early 2023, Erginbilgic had overseen a restructuring of the company, including the elimination of 2,500 jobs and efforts to resolve long-standing supply chain disruptions.

Under his leadership, Rolls-Royce's share price had surged from around 150p to over 800p, with a notable rise following a recent London defence summit where European leaders reaffirmed their commitment to increased military spending.

The company's recent financial success marked a stark contrast to the difficulties faced in previous years when the pandemic severely impacted its aviation business, forcing Rolls-Royce to raise emergency funding.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.